Share Twitter LinkedIn Facebook Email Dr. Mark Kris, MD of Memorial Sloan Kettering discusses the role of MET in NSCLC and why earlier TKIs and antibodies have been disappointing.
ASH 2025 MDS/ALL Highlights: Verona Trial Lessons & CLEVER Pathway | Dr. Jeyakumar Acute Lymphoblastic Leukemia 5 Mins Read
Advancing Acute Lymphoblastic Leukemia Treatment with CAR-T Cells: Insights from Dr. Anjali Advani Acute Lymphoblastic Leukemia 3 Mins Read
